NCT05958381 Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
| NCT ID | NCT05958381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas at Dallas |
| Condition | Multiple Sclerosis, Relapsing-Remitting |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-10-18 |
| Primary Completion | 2026-06-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-10-18 with a primary completion date of 2026-06-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.
Eligibility Criteria
Inclusion Criteria: º Diagnosed with relapsing-remitting multiple sclerosis (RRMS) º Memory retrieval deficit based on neuropsychological testing done in our lab º Must be fluent in speaking and reading English. Exclusion Criteria: º Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing º Participants using benzodiazepines must have been on a stable dose for at least two months º Potentially confounding psychological or neurological disorder, including: * dementia of any type * epilepsy or other seizure disorders * severe traumatic brain injury * brain tumor * present drug abuse * stroke * blood vessel abnormalities in the brain * Parkinson's disease * Huntington's disease º inability to give informed consent º cranial implants º skull defects that affect tDCS administration º use of medications that interact with or potentially interact with tDCS effects, including: * anti-convulsants * L-dopa * carbamazepine * sulpiride * pergolide * lorazepam * rivastigmine * dextromethorphan * D-cycloserine * flunarizine * ropinirole * stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) must be stopped during enrollment
Contact & Investigator
John Hart, Jr, MD
PRINCIPAL INVESTIGATOR
The University of Texas at Dallas
Frequently Asked Questions
Who can join the NCT05958381 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis, Relapsing-Remitting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05958381 currently recruiting?
Yes, NCT05958381 is actively recruiting participants. Contact the research team at Ashna.Adhikari@UTDallas.edu for enrollment information.
Where is the NCT05958381 trial being conducted?
This trial is being conducted at Richardson, United States.
Who is sponsoring the NCT05958381 clinical trial?
NCT05958381 is sponsored by The University of Texas at Dallas. The principal investigator is John Hart, Jr, MD at The University of Texas at Dallas. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.